- Home
- UNF vs BTAI Comparison
UNF vs BTAI Comparison
Compare UNF & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNF
- BTAI
- Stock Information
- Founded
- UNF 1936
- BTAI 2017
- Country
- UNF United States
- BTAI United States
- Employees
- UNF N/A
- BTAI N/A
- Industry
- UNF Business Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- UNF Consumer Discretionary
- BTAI Health Care
- Exchange
- UNF Nasdaq
- BTAI Nasdaq
- Market Cap
- UNF N/A
- BTAI 10.7M
- IPO Year
- UNF N/A
- BTAI 2018
- Fundamental
- Price
- UNF $184.05
- BTAI $1.53
- Analyst Decision
- UNF Sell
- BTAI Buy
- Analyst Count
- UNF 4
- BTAI 5
- Target Price
- UNF $180.00
- BTAI $42.60
- AVG Volume (30 Days)
- UNF 106.8K
- BTAI 71.7K
- Earning Date
- UNF 06-25-2025
- BTAI 05-20-2025
- Dividend Yield
- UNF 0.76%
- BTAI N/A
- EPS Growth
- UNF 31.42
- BTAI N/A
- EPS
- UNF 8.04
- BTAI N/A
- Revenue
- UNF $2,450,322,000.00
- BTAI $2,266,000.00
- Revenue This Year
- UNF $1.01
- BTAI $41.00
- Revenue Next Year
- UNF $3.83
- BTAI $197.21
- P/E Ratio
- UNF $22.80
- BTAI N/A
- Revenue Growth
- UNF 5.04
- BTAI 64.20
- 52 Week Low
- UNF $149.58
- BTAI $1.29
- 52 Week High
- UNF $243.70
- BTAI $42.08
- Technical
- Relative Strength Index (RSI)
- UNF 57.85
- BTAI 37.55
- Support Level
- UNF $177.78
- BTAI $1.60
- Resistance Level
- UNF $186.21
- BTAI $2.09
- Average True Range (ATR)
- UNF 3.77
- BTAI 0.15
- MACD
- UNF 1.69
- BTAI -0.00
- Stochastic Oscillator
- UNF 85.74
- BTAI 5.08
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.